Non small cell lung cancer management

Non Small Cell Lung Cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Non Small Cell Lung Cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
CT Scan
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Management Approach Stage I Stage II Stage III Stage IV Metastatic Cancer
Medical Therapy Chemotherapy Radiation Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Non small cell lung cancer management On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Non small cell lung cancer management All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Non small cell lung cancer management
CDC on Non small cell lung cancer management
Non small cell lung cancer management in the news
Blogs on Non small cell lung cancer management
Directions to Hospitals Treating Non small cell carcinoma of the lung
Risk calculators and risk factors for Non small cell lung cancer management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Management Approach

• The table below summarizes the different standard treatment options according to the TNM criteria for non-small cell lung cancer

Standard Treatment Options Adapted from Non-Small Cell Lung Cancer Treatment (PDQ® 2016)
Stage (TNM criteria)	Standard Treatment Options
Occult	Surgery
Stage 0	Surgery Endobronchial therapies
Stages IA and IB	Surgery Radiation therapy IB, if the tumor is >4cm, surgery and chemotherapy
Stages IIA and IIB	Surgery Neoadjuvant chemotherapy Adjuvant chemotherapy Radiation therapy
Stage IIIA	Resected or resectable disease Surgery Neoadjuvant therapy Adjuvant therapy Unresectable disease Radiation therapy Chemoradiation therapy Superior sulcus tumors Radiation therapy alone Radiation therapy and surgery Concurrent chemotherapy with radiation therapy and surgery Surgery alone (for selected patients) Tumors that invade the chest wall Surgery Surgery and radiation therapy Radiation therapy alone Chemotherapy combined with radiation therapy and/or surgery
Stage IIIB	Sequential or concurrent chemotherapy and radiation therapy Chemotherapy followed by surgery (for selected patients) Radiation therapy alone
Stage IV	Cytotoxic combination chemotherapy (first line) Combination chemotherapy with bevacizumab or cetuximab EGFR tyrosine kinase inhibitors (first line) EML4-ALK inhibitors in patients with EML-ALK translocations Immune checkpoint inhibition with nivolumab for selected patients with squamous or nonsquamous metastatic Maintenance therapy following first-line chemotherapy Endobronchial laser therapy and/or brachytherapy (for obstructing lesions) External-beam radiation therapy (primarily for palliation of local symptomatic tumor growth)
Recurrent	Radiation therapy (for palliation) Chemotherapy or kinase inhibitors alone EGFR inhibitors in patients with/without EGFR mutations EML4-ALK inhibitors in patients with EML-ALK translocations Surgical resection of isolated cerebral metastasis (for highly selected patients) Laser therapy or interstitial radiation therapy (for endobronchial lesions) Stereotactic radiation surgery (for highly selected patients)